Novel Associations of Empagliflozin on the Gut Microbiome and Metabolome in Type 2 Diabetes

J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4246-e4247. doi: 10.1210/clinem/dgac329.

Authors

Ashani Lecamwasam^{1

2

3}, Elif I Ekinci^{1

2

4}

Affiliations

¹ Department of Endocrinology, Austin Health, Victoria, Australia.
² Department of Medicine, University of Melbourne, Victoria, Australia.
³ Department of Nephrology, Northern Health, Victoria, Australia.
⁴ Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Australia.

PMID: 35674101
DOI: 10.1210/clinem/dgac329

No abstract available

Keywords: cardiovascular disease; empagliflozin; gut microbiota; metabonomics; type 2 diabetes mellitus.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / metabolism
Gastrointestinal Microbiome*
Glucosides / therapeutic use
Humans
Metabolome

Substances

Benzhydryl Compounds
Glucosides
empagliflozin